Organovo(ONVO)

Search documents
Organovo(ONVO) - 2026 Q1 - Quarterly Report
2025-08-12 20:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35996 VivoSim Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 27-1488943 (State or other jurisdiction of incorporat ...
Will the ONVO L90's Fast Market Entry Boost NIO's Competitive Edge?
ZACKS· 2025-07-23 15:00
Core Insights - NIO Inc.'s sub-brand ONVO is launching the L90 flagship electric SUV, with test drives starting in China and deliveries expected to begin on August 1, 2025 [1][2][10] Product Launch and Features - The L90 will officially launch on July 31, 2025, with pre-sales starting on July 10, 2025 [2] - The starting price for the L90 is RMB 279,900 with an 85-kWh battery, which can be reduced to RMB 193,900 under the Battery-as-a-Service rental option [3] - The L90 includes high-end features such as 900V fast charging, an AR head-up display, adjustable air suspension, a built-in smart refrigerator, and Level 2+ driver assistance systems powered by Nvidia's Orin-X chip [4][10] Competitive Landscape - Li Auto Inc. is set to unveil its electric SUV, the Li i8, on July 29, 2025, with pre-sales starting on July 17, 2025, and a price range of RMB 350,000 to RMB 400,000 [6] - XPeng Inc. launched the G7 at a starting price of RMB 195,800, which is lower than its initial pre-sale price of RMB 235,800 [7] Financial Performance - NIO has outperformed the Zacks Automotive-Domestic industry year-to-date, with shares gaining 14.9% compared to the industry's decline of 7.2% [8] - NIO's price/sales ratio indicates it is trading at a forward sales multiple of 0.66, which is higher than the industry's 0.45, suggesting potential overvaluation [11] Earnings Estimates - The Zacks Consensus Estimate for 2025 EPS has increased by 16 cents in the past 60 days, while the estimate for 2026 EPS has decreased by one cent in the past 30 days [12]
Organovo(ONVO) - 2025 Q4 - Annual Report
2025-06-05 20:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File No. 001-35996 VIVOSIM LABS, INC. (Exact name of registrant as specified in its charter) | Delaware 27-1488943 | | | --- | --- | | (State or other j ...
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market
Newsfilter· 2025-04-24 12:05
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development. VivoSim will offer liver and intestinal toxicology insights using its premier new approach methodologies (NAM) models, following the announcement of the FDA to phase out animal testing requirements in favor of these non-animal NAM methods. The FDA's push to phase out animal models, announced on April 10, is expec ...
VivoSim to Carry Forward Organovo 3D Bioprinting
Globenewswire· 2025-04-23 12:05
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (the “Company”) announced that it will carry forward its 3D bioprinting and legacy technology as VivoSim Labs, Inc. A name change of the Company to VivoSim Labs, Inc. will be effective on April 24, 2025, and the Company’s common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol “VIVS” at market open on April 24, 2025. No action is required by existing stockholders with respect to the name and ...
Organovo(ONVO) - 2025 Q4 - Annual Results
2025-04-02 12:06
Financial Performance and Compliance - Organovo Holdings reported preliminary unaudited cash for the fiscal year ending March 31, 2025, and expects to meet all requirements for continued listing on the Nasdaq Capital Market[6]. - The company had stockholders' equity of $364,000 as of December 31, 2024, which did not meet Nasdaq's minimum requirement of $2,500,000[10]. - Following the asset sale and other financial activities, the company believes it has a minimum of $2,500,000 in stockholders' equity as of April 2, 2025[12]. - The company received a notice from Nasdaq indicating it did not meet the minimum bid price requirement of $1.00 per share[10]. - The company presented its compliance plan to the Nasdaq Hearings Panel on February 27, 2025, and was granted an exception until April 15, 2025, to demonstrate compliance[10]. - Forward-looking statements indicate potential risks and uncertainties regarding compliance with Nasdaq listing requirements[13]. Asset Sale - On March 25, 2025, Organovo completed the sale of its FXR program to Eli Lilly for an upfront cash payment of $10.0 million, with potential milestone payments of up to $50.0 million[11]. Financial Strategy - The company has engaged in warrant exercises and sales of common stock to improve its financial position[12]. - Organovo's financial information is subject to adjustments based on the completion of customary annual audit procedures[6]. Company Classification - The company is classified as an emerging growth company under the Securities Act[5].
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements
Globenewswire· 2025-04-02 12:05
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today reported preliminary unaudited cash for the fiscal year ending March 31, 2025, and net cash utilization results for the fiscal fourth quarter of 2025. The Company expects to release full fiscal second-quarter financial results the week of June 9-13, 2025. The Compa ...
Organovo Provides Business Update
Globenewswire· 2025-03-27 12:05
Core Insights - Organovo Holdings, Inc. is a clinical stage biotechnology company focused on developing novel treatment approaches for inflammatory bowel disease (IBD) [1] Group 1: Business Update - The company has completed the sale of its FXR Program to Lilly, receiving upfront payments and anticipating future milestone payments [2] - Organovo expects a decrease in expenditures in the coming year due to the elimination of costs associated with the FXR314 program, allowing for a more efficient use of existing capital [2] - The company plans to report its full year financials for the fiscal year ended March 31, 2025, around June 6-10, 2025 [2] Group 2: Research and Development - Organovo utilizes 3D human cellular models of Crohn's disease and ulcerative colitis to evaluate therapeutic opportunities, believing these models increase the likelihood of success in clinical trials [3] - In 2024, FXR314 showed strong performance in improving epithelial barrier function and fibrotic activity in ulcerative colitis models, as presented at the Crohn's and Colitis Congress [3] - FXR314 demonstrated synergistic benefits when paired with an approved Janus kinase (JAK) inhibitor, indicating potential for combination therapies [3] Group 3: Company Overview - Organovo is developing drugs that are effective in 3D human tissues, utilizing proprietary technology to create tissues that mimic native human tissue characteristics [4]
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
Globenewswire· 2025-03-25 15:25
Core Insights - Organovo Holdings, Inc. has successfully closed the sale of its FXR program, including the lead asset FXR314, to Eli Lilly and Company on March 25, 2025 [1][2] Company Overview - Organovo is a clinical stage biotechnology company focused on developing drugs that are effective in three-dimensional (3D) human tissues, utilizing proprietary technology to create 3D human tissues that replicate key aspects of native human tissue [3]
Organovo Announces Reverse Stock Split
Globenewswire· 2025-03-19 12:05
Core Points - Organovo Holdings, Inc. announced a 1-for-12 reverse stock split effective March 20, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][5]. - The reverse stock split will reduce the number of issued and outstanding shares from approximately 21.4 million to about 1.8 million, without changing the par value of $0.001 per share [3][5]. - The company will continue trading under the symbol "ONVO" on the Nasdaq Capital Market with a new CUSIP number [2]. Company Information - Organovo is a clinical stage biotechnology company focused on developing novel treatment approaches for inflammatory bowel disease (IBD) and utilizes proprietary technology to create 3D human tissues for drug development [7]. - The reverse stock split was approved by stockholders at the annual meeting on November 20, 2024, allowing the board to select a split ratio between 1-for-5 and 1-for-20 [5]. - Following the reverse split, the number of shares available under equity incentive plans will be proportionately adjusted [4].